AstraZeneca’s 3rd generation EGFR mutation-positive non-small cell lung cancer (NSCLC) treatment ‘Tagrisso (osimertinib)’ has shown consistent effects with the clinical trial results in practice. In the real world, Tagrisso demonstrated excellent treatment effects even in patients with brain metastasis, poor systemic condition, or patients with rare mutations.

The real-world study results from Germany and Japan that contained the results above were presented at the ESMO Asia 2022 Congress that has been held in Singapore on the 2nd. The large-scale, real-world studies evaluated the use of Tagrisso as a first-line treatment in the field on 600 patients in Japan and 200 patients in Germany.